
MAIN RECOMMENDATIONS 1 ESGE/EASL recommend that, as the primary diagnostic modality for PSC, magnetic resonance cholangiography (MRC) should be preferred over endoscopic retrograde cholangiopancreatography (ERCP).Moderate quality evidence, strong recommendation. 2 ESGE/EASL suggest that ERCP can be considered if MRC plus liver biopsy is equivocal or contraindicated in patients with persisting clinical suspicion of PSC. The risks of ERCP have to be weighed against the potential benefit with regard to surveillance and treatment recommendations.Low quality evidence, weak recommendation. 6 ESGE/EASL suggest that, in patients with an established diagnosis of PSC, MRC should be considered before therapeutic ERCP.Weak recommendation, low quality evidence. 7 ESGE/EASL suggest performing endoscopic treatment with concomitant ductal sampling (brush cytology, endobiliary biopsies) of suspected significant strictures identified at MRC in PSC patients who present with symptoms likely to improve following endoscopic treatment.Strong recommendation, low quality evidence. 9 ESGE/EASL recommend weighing the anticipated benefits of biliary papillotomy/sphincterotomy against its risks on a case-by-case basis.Strong recommendation, moderate quality evidence.Biliary papillotomy/sphincterotomy should be considered especially after difficult cannulation.Strong recommendation, low quality evidence. 16 ESGE/EASL suggest routine administration of prophylactic antibiotics before ERCP in patients with PSC.Strong recommendation, low quality evidence. 17 EASL/ESGE recommend that cholangiocarcinoma (CCA) should be suspected in any patient with worsening cholestasis, weight loss, raised serum CA19-9, and/or new or progressive dominant stricture, particularly with an associated enhancing mass lesion.Strong recommendation, moderate quality evidence. 19 ESGE/EASL recommend ductal sampling (brush cytology, endobiliary biopsies) as part of the initial investigation for the diagnosis and staging of suspected CCA in patients with PSC.Strong recommendation, high quality evidence.
Cholangiopancreatography, Endoscopic Retrograde, Hepatology, Cholangiopancreatography, Magnetic Resonance, Primary sclerosing cholangitis, Biopsy, Cholangitis, Sclerosing, Gastroenterology, EMC MM-04-20-01, Antibiotic Prophylaxis, Inflammatory Bowel Diseases, Dilatation, Magnetic Resonance Imaging, Cholangiocarcinoma, Sphincterotomy, Endoscopic, Bile Duct Neoplasms, Gastro-entérologie, Humans, Stents, Endoscopy, Digestive System, Cholangiography
Cholangiopancreatography, Endoscopic Retrograde, Hepatology, Cholangiopancreatography, Magnetic Resonance, Primary sclerosing cholangitis, Biopsy, Cholangitis, Sclerosing, Gastroenterology, EMC MM-04-20-01, Antibiotic Prophylaxis, Inflammatory Bowel Diseases, Dilatation, Magnetic Resonance Imaging, Cholangiocarcinoma, Sphincterotomy, Endoscopic, Bile Duct Neoplasms, Gastro-entérologie, Humans, Stents, Endoscopy, Digestive System, Cholangiography
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 258 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 1% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 1% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 0.1% |
